Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 548Genetic factors in colorectal cancerCancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

The DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index.

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Open access

Published version of a preprint

Abstract

To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability–high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/β-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/β-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion. Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730–49. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 663

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1327

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
Figure 1 Frequently mutated genes in CRC
Figure 1 Frequently mutated genes in CRCCC-BY · From the PDF
Figure 2 Data sets and summary of significantly mutated genes
Figure 2 Data sets and summary of significantly mutated genesCC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
Image 6
CC-BY · From the PDF
Image 7
CC-BY · From the PDF
Single-copy losses with disruptive mutations (MSS)
Single-copy losses with disruptive mutations (MSS)CC-BY · From the PDF
Figure 3 Biallelic loss events in significantly mutated genes in CRC broken down by MSI status a , Stacked barplot showing genes with recurrent biallelic disruptions in MSS and MSI-high tumors, by number of biallelic disruptions of each type. b , CN-LOH and single copy loss events in MSI-high and MSS. Each panel shows all disruptive somatic mutations (i.e., splice-site mutations, nonsense mutations, start site mutations, and frame-shift indels) that overlap single-copy losses and CN-LOH events. Each horizontal segment represents a single event, with the length of the segment proportional to the length of the alteration; colored dots represent mutations.
Figure 3 Biallelic loss events in significantly mutated genes in CRC broken down by MSI status a , Stacked barplot showing genes with recurrent biallelic disruptions in MSS and MSI-high tumors, by number of biallelic disruptions of each type. b , CN-LOH and single copy loss events in MSI-high and MSS. Each panel shows all disruptive somatic mutations (i.e., splice-site mutations, nonsense mutations, start site mutations, and frame-shift indels) that overlap single-copy losses and CN-LOH events. Each horizontal segment represents a single event, with the length of the segment proportional to the length of the alteration; colored dots represent mutations.CC-BY · From the PDF
Figure 4 Mutation landscape of immune-related genes and consequences in MSI-high tumors a , Mutation landscape of 9 genes frequently mutated in MSI-high and involved in antigen presentation, as well as 11 significantly mutated immune-related genes that regulate other hematopoietic cell types beyond antigen presentation. Gene expression for HLA Class I (red bar) and Class II (blue bar) genes is shown for comparison. Total number of coding mutations in MSS samples for each gene is shown to the left. Samples were clustered by gene expression; the four main clusters are indicated above the dendrogram: Cluster I (green), Cluster II (purple), Cluster III (yellow), and Cluster IV (orange) bars). b , Decreases in HLA-A and HLA-B expression in samples with disruptive mutations in those genes. c , Decreases in HLA Class I gene expression in samples with mutations in either NLRC5 or RFX5. d , Decreases in TAP2 and B2M expression in samples with disruptive mutations in those genes. (* P<0.01, ** P<0.001, *** P<1.0×10 -4 for b -d .) e , Mutation counts in pathways affecting antigen presentation broken down by type.
Figure 4 Mutation landscape of immune-related genes and consequences in MSI-high tumors a , Mutation landscape of 9 genes frequently mutated in MSI-high and involved in antigen presentation, as well as 11 significantly mutated immune-related genes that regulate other hematopoietic cell types beyond antigen presentation. Gene expression for HLA Class I (red bar) and Class II (blue bar) genes is shown for comparison. Total number of coding mutations in MSS samples for each gene is shown to the left. Samples were clustered by gene expression; the four main clusters are indicated above the dendrogram: Cluster I (green), Cluster II (purple), Cluster III (yellow), and Cluster IV (orange) bars). b , Decreases in HLA-A and HLA-B expression in samples with disruptive mutations in those genes. c , Decreases in HLA Class I gene expression in samples with mutations in either NLRC5 or RFX5. d , Decreases in TAP2 and B2M expression in samples with disruptive mutations in those genes. (* P<0.01, ** P<0.001, *** P<1.0×10 -4 for b -d .) e , Mutation counts in pathways affecting antigen presentation broken down by type.CC-BY · From the PDF
Figure 5 WNT signaling anti-correlated with T-cell infiltration , Mutation landscape of significantly mutated genes involved in WNT signaling in MSS
Figure 5 WNT signaling anti-correlated with T-cell infiltration , Mutation landscape of significantly mutated genes involved in WNT signaling in MSSCC-BY · From the PDF
Figure 6 APC biallelic loss a genomic driver of immunosuppression of TILs by WNT-signaling a , Scatterplot showing T-cell average versus AXIN2 gene expression for MSS biallelic APC loss cases (APC++), MSI-high biallelic APC loss cases, and MSS and MSI-high cases without disruptive mutations in APC (APC-). b , Differences in AXIN2 expression and T-cell average for all CRC samples without APC disruptive mutations (APC-) and with biallelic APC disruptive mutations (APC++). c , Differences in AXIN2 expression and T-cell average for samples without APC disruptive mutations and with biallelic APC disruptive mutations separated by MSS and MSI-high status (* P<0.01, ** P<0.001, *** P<1.0×10 -4 ; NS: not significant).
Figure 6 APC biallelic loss a genomic driver of immunosuppression of TILs by WNT-signaling a , Scatterplot showing T-cell average versus AXIN2 gene expression for MSS biallelic APC loss cases (APC++), MSI-high biallelic APC loss cases, and MSS and MSI-high cases without disruptive mutations in APC (APC-). b , Differences in AXIN2 expression and T-cell average for all CRC samples without APC disruptive mutations (APC-) and with biallelic APC disruptive mutations (APC++). c , Differences in AXIN2 expression and T-cell average for samples without APC disruptive mutations and with biallelic APC disruptive mutations separated by MSS and MSI-high status (* P<0.01, ** P<0.001, *** P<1.0×10 -4 ; NS: not significant).CC-BY · From the PDF
Figure 7 AXIN2 super-enhancer hypomethylation a cis-driver of immunosuppression of TILs by WNT-signaling
Figure 7 AXIN2 super-enhancer hypomethylation a cis-driver of immunosuppression of TILs by WNT-signalingCC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 103 references

Cited by

See all 548

Metadata

Authors
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., Morikawa, T., Nosho, K., Abril-Rodriguez, G., Connolly, C., Escuin-Ordinas, H., Geybels, M. S., Grady, W. M., Hsu, L., Hu-Lieskovan, S., Huyghe, J. R., Kim, Y. J., Krystofinski, P., Leiserson, M. D. M., Montoya, D. J., Nadel, B. B., Pellegrini, M., Pritchard, C. C., Puig-Saus, C., Quist, E. H., Raphael, B. J., Salipante, S. J., Shin, D. S., Shinbrot, E., Shirts, B., Shukla, S., Stanford, J. L., Sun, W., Tsoi, J., Upfill-Brown, A., Wheeler, D. A., Wu, C. J., Yu, M., Zaidi, S. H., Zaretsky, J. M., Gabriel, S. B., Lander, E. S., Garraway, L. A., Hudson, T. J., Fuchs, C. S., Ribas, A., Ogino, S., & Peters, U.
Affiliations
  • University of California, Los Angeles (US)
  • Broad Institute (US)
  • Parker Institute for Cancer Immunotherapy (US)
  • Dana-Farber Cancer Institute (US)
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
  • 1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Fred Hutch Cancer Center (US)
  • University of Washington (US)
  • Brown University (US)
  • 13Department of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, Rhode Island.
  • Baylor College of Medicine (US)
  • Ontario Institute for Cancer Research (CA)
Corresponding author
Grasso, Catherine S.
Venue
Cancer Discovery
Published
2018-05-31
Volume
8
Issue
6
Pages
730-749
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2793126529
Cited by
535
References
103
Citations by year
2026: 47 · 2025: 42 · 2024: 49 · 2023: 73 · 2022: 83 · 2021: 80 · 2020: 76 · 2019: 58 · 2018: 25
FWCI
45.45
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Discovery (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
  • HAL (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • HHS | National Institutes of Health (NIH) (U01 CA137088, K07 CA190673, 1R01CA194663-01, R35 CA197663, P01 CA168585, KL2 TR001100, U54 HG003067, 4T32CA009120-40, P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, P50 CA127003, R35 CA197735, R01 CA151993)
  • American Association for Cancer Research (AACR) (SU2C-AACR-DT22-17)
  • HHS | NIH | National Cancer Institute (NCI) (5T32LM012424-03)
  • HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3P50AR063020-03S1)
  • Dana-Farber/Harvard Cancer Center (DF/HCC) (Nodal Award)
  • American Society of Clinical Oncology (ASCO) (Career Development Award)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
colorectal cancer, immune evasion, microsatellite instability-high, Wnt/β-catenin signaling, T-cell exclusion, immunoediting, antigen presentation, beta2-microglobulin, HLA, copy-neutral loss of heterozygosity, copy number alterations, DNA methylation, immune checkpoint inhibitor resistance, tumor mutational burden, T cell infiltration
MeSH terms
beta 2-Microglobulin, HLA Antigens, Humans, Colorectal Neoplasms, Germ-Line Mutation, Tumor Escape, DNA Methylation, Loss of Heterozygosity, Microsatellite Instability, DNA Copy Number Variations, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Mechanisms of Immune Evasion in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-1327
The paper
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., Morikawa, T., Nosho, K., Abril-Rodriguez, G., Connolly, C., Escuin-Ordinas, H., Geybels, M. S., Grady, W. M., Hsu, L., Hu-Lieskovan, S., . . . Peters, U. (2018). Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-1327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.